Answers are grounded in this paper and cite their sources.
Background Although prostate‐specific membrane antigen (PSMA) positron emission tomography (PET) imaging is increasingly standard for prostate tumor staging at diagnosis, the molecular correlates of PSMA expression are underexplored. Methods Digitally quantified PSMA protein expression was correlated with clinical‐pathologic, immune microenvironment, and molecular features of primary tumors, including those with paired pelvic lymph node metastases. The association of primary tumor ERG fusion status with radiotracer uptake was tested in three clinical trials of initial staging 18 F‐DCFPyL PSMA PET imaging. The association of ERG status with PSMA PET sensitivity for pelvic lymph node metastasis was examined in men undergoing initial PET staging. Results Primary tumor PSMA expression did not vary by self‐identified race or genetic ancestry and was negatively correlated with tumor T‐ and B‐lymphocyte densities. Primary tumors with ERG fusions expressed less PSMA than those without, but this association was not maintained for pelvic lymph node metastases. ERG fusion‐positive primary tumors had lower maximum standardized uptake values compared to ERG fusion‐negative tumors in two of three clinical trials. Among pN1 patients with preoperative imaging, the sensitivity of PSMA PET for nodal metastases was not significantly different by ERG status, although this study was limited by its retrospective and correlative nature. Conclusions PSMA PET primary tumor visualization may be limited by lower expression of PSMA in tumors with ERG fusions, with implications for PET‐based primary tumor staging. However, there is no evidence for decreased PSMA expression—or altered sensitivity of PSMA PET—in lymph node metastases from ERG fusion‐positive tumors.
No takes yet. Share an insight, caveat, or question.
Dairo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: